Johnson & Johnson (JNJ)

As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities.

Kimberly-Clark is far from flashy, but what it lacks in glitz and glam, it makes up for with predictability.

These stocks have long histories of growing their payouts to shareholders.

They may not remain cheap for too much longer.

Good medical care will always be in high demand, which makes some healthcare stocks strong long-term picks.

Investors can count on these stocks about as much as any to continue their decades-long runs of excellence.

These three healthcare stocks provide stability, relatively high dividend yields, and consistent growth.

JNJ will release its Q2 earnings on July 15, with analysts expecting earnings of $2.85 per share and revenue of $25.05 billion. Stock rose 3.6%.

Johnson & Johnson doesn't need GLP-1 drugs to grow, and that's good news for long-term investors.

Politicians serve on committees that set healthcare policy, monitor government contracts, and shape regulatory frameworks.

Bristol Myers Squibb trades at a deep discount, while Johnson & Johnson boasts higher margins and a broader reach. How do their financials and risks stack up?

It can provide some stability during volatile times.